Rapid improvement of renal microcirculatory homeostasis by liraglutide following diabetes induction.
Diabetes Obes Metab · 2026
Last updated 2026-05-28In a study on mice with type 2 diabetes, short-term treatment with liraglutide (1-2 weeks) improved kidney blood flow and oxygen levels, which were initially disrupted by diabetes. Both liraglutide and insulin reduced signs of kidney damage, such as fibrosis, and improved kidney function markers like creatinine. Liraglutide also helped restore levels of certain amino acids linked to healthy blood vessels.
AI summary of the abstract below.
| Journal | Diabetes Obes Metab, 2026 |
|---|---|
| Citations | 0 |
| Molecules | liraglutide |
| Conditions studied | Type 2 Diabetes, Chronic Kidney Disease |
Abstract
AIMS: Renal microvascular dysfunction is a central driver of diabetic kidney disease, yet the potential for rapid therapeutic reversal remains obscure. We investigated the effect of short-term liraglutide on early changes in the renal microcirculation post-induction of diabetes.
MATERIALS AND METHODS: Type 2 diabetes mellitus (T2DM) was induced in BALB/c mice via high-fat diet and streptozotocin. Following induction, mice received insulin or liraglutide treatments for 1 or 2 weeks. Renal microhemodynamics was analysed using laser Doppler flowmetry and wavelet analysis. Histopathological evaluations via Masson trichrome and haematoxylin-eosin staining assessed fibrosis and microvascular integrity. Primary renal microvascular endothelial cells (RMECs) were isolated to evaluate angiogenic and migratory behaviours. Metabolomics analyses were performed to link metabolic changes with microcirculatory alterations.
RESULTS: T2DM induced significant impairments in renal microcirculation, characterised by dysregulated microhemodynamics, disturbed oxygen saturation, altered haemoglobin distribution and compromised blood perfusion. These functional defects were accompanied by elevated creatinine, reduced cystatin C and impaired angiogenic and migratory capacity of RMECs under glucotoxicity. Both insulin and liraglutide treatments ameliorated renal microcirculatory oxygen profiles and improved renal function biomarkers. Histological data revealed decreased fibrosis and enhanced microvascular architecture post-treatment. Metabolomic profiling revealed that liraglutide preferentially restored depleted amino acid levels associated with microvascular function, a change associated with the normalisation of metabolic profiles potentially involving peptide transport pathways.
CONCLUSIONS: Our findings demonstrate that short-term liraglutide restores renal microcirculatory homeostasis in the post-induction phase, mitigating microvascular dysfunction and preserving kidney structure, highlighting the potential therapeutic value in preventing the progression of diabetic renal injury.
Verbatim abstract via PubMed 41749403 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.